Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co. Inc. daily Stock Chart
MRK [NYSE]
Merck & Co. Inc.
IndexDJIA S&P500 P/E14.98 EPS (ttm)3.85 Insider Own0.04% Shs Outstand2.83B Perf Week-0.40%
Market Cap162.93B Forward P/E15.12 EPS next Y3.82 Insider Trans-34.17% Shs Float2.82B Perf Month-3.78%
Income11.17B PEG3.68 EPS next Q0.80 Inst Own75.30% Short Float1.14% Perf Quarter1.77%
Sales41.40B P/S3.94 EPS this Y176.90% Inst Trans-0.51% Short Ratio3.04 Perf Half Y3.15%
Book/sh16.85 P/B3.42 EPS next Y10.84% ROA11.00% Target Price65.47 Perf Year0.68%
Cash/sh5.52 P/C10.44 EPS next 5Y4.07% ROE23.50% 52W Range51.29 - 62.63 Perf YTD3.15%
Dividend1.80 P/FCF124.56 EPS past 5Y-6.30% ROI0.50% 52W High-7.92% Beta0.37
Dividend %3.12% Quick Ratio1.30 Sales past 5Y9.00% Gross Margin61.40% 52W Low12.44% ATR0.89
Employees70000 Current Ratio1.60 Sales Q/Q-8.20% Oper. Margin37.70% RSI (14)44.37 Volatility1.66% 1.36%
OptionableYes Debt/Eq0.63 EPS Q/Q-42.10% Profit Margin27.00% Rel Volume0.81 Prev Close57.60
ShortableYes LT Debt/Eq0.53 EarningsJul 28 BMO Payout45.30% Avg Volume10.55M Price57.67
Recom2.40 SMA20-0.91% SMA50-1.97% SMA200-0.66% Volume8,518,380 Change0.12%
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Jul-04-15 11:39AM  I lived the nightmare that keeps anti-vaccine advocates up at night and I'm still not on their side
Jul-03-15 11:33AM  Hospira wins French biosimilar drug tender at 45 pct discount
Jul-02-15 03:44PM  Something terrible happened to me when I got a vaccine, but I'm still a believer
03:04PM  2015 Forbes Women's Summit: Full Session Videos at Forbes
11:16AM  Why Illumina The "Marvel" May See a Stock Rise
09:43AM  US stocks open higher as Street eyes jobs, Greece at CNBC
Jun-30-15 04:50PM  Celldex's Rintega Phase III Study Recommended to Continue - Analyst Blog
Jun-29-15 08:30AM  Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy Business Wire
Jun-26-15 08:37PM  A Makeover at the Other Merck at The Wall Street Journal
04:01PM  The 4 Stocks That Lifted the Dow on Friday at 24/7 Wall St.
08:00AM  Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28 Business Wire
Jun-25-15 08:10AM  Short Sellers Become More Focused on Big Pharma at 24/7 Wall St.
Jun-23-15 09:00AM  How Apple, Google and 7 Other Cash-Hoarding Companies Will Spend Their Billions at TheStreet
Jun-22-15 04:35PM  Merck (MRK) Stock Closed Up on Encouraging New Drug Pipeline at TheStreet
05:40AM  Gardasil-9 Effectively Stops 90 Percent Of Cancers Caused By HPV In Girls and Boys at Forbes
Jun-21-15 07:13PM  Barron's Recap: Airline Stocks Ready To Soar
Jun-20-15 12:17AM  Merck's New Drugs Could Produce Big Profits at Barrons.com
Jun-18-15 04:28PM  Inspire Pharma with deep Triangle roots settles civil fraud claim at bizjournals.com
09:10AM  Apple and 10 Big Companies That Hoard the Most Cash at TheStreet
Jun-17-15 05:45PM  Sigma-Aldrich's Buyout by Merck KGaA Gets EC Clearance - Analyst Blog
05:13PM  Inspire Pharmaceuticals Settles Federal Fraud Claims at The Wall Street Journal
04:29PM  Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.
12:21PM  Why Bristol-Myers Squibb Could Fall Nearly 10% at Barrons.com
09:42AM  Merck (MRK) Stock Coverage Initiated at Piper Jaffray at TheStreet
07:07AM  Coverage initiated on Merck by Piper Jaffray
Jun-16-15 05:52PM  Merck Manuals health guides go digital, and free, in global push
Jun-15-15 03:04PM  Moody's: Immuno-oncology drugs credit positive for drug makers; competition high at Moody's
02:58PM  Will Merck (MKGAY) Stock be Helped by EC Approval of $17 Billion Sigma-Aldrich Deal? at TheStreet
01:40PM  European Commission approves Merck's $17 bln Sigma-Aldrich buy Reuters
08:55AM  AstraZeneca R&D executive Morrison to lead cancer firm Syndax
Jun-14-15 03:15AM  Merck Serono: Innovative Fertility Technologies Gavi and Geri of Partner Genea Biomedx Receive CE Mark CNW Group
Jun-13-15 07:10AM  What You May Have Missed In Biotech: $100M For Antibiotics And Good News For Postpartum Depression at Forbes
Jun-12-15 04:21PM  Obamas Pacific trade deal will help these sectors if it passes at MarketWatch
12:56PM  Merck Betting High On Immunotherapy And HCV Drugs Market For Strong Comeback
11:23AM  Is Excitement Over Eli Lilly's Alzheimer's Drug Overdone? at Barrons.com
Jun-11-15 06:57PM  Cramer: Massive biotech moves that make sense at CNBC
04:30PM  Merck (MRK) Presents Multiple Biosimilar and Diabetes Data - Analyst Blog
02:00PM  Two Cambridge biotechs launch legal battle over trade secrets at bizjournals.com
10:39AM  Agenus (AGEN) Stock Higher Following Coverage Initiation at TheStreet
10:19AM  How to Trade 5 Big Stocks for Big Gains -- Must-See Charts at TheStreet
09:00AM  Liaison Technologies and Merck Cut the Ribbon for a Collaborative Innovation Center on NC State's Centennial Campus PR Newswire
08:00AM  Merck Launches New Program That Encourages Women to "Rule the Real Talk" and Prioritize Their Sexual Health PR Newswire
Jun-10-15 01:35PM  Esperion Therapeutics: Why Regeneron Decision is Bad News at Barrons.com
08:46AM  Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints Business Wire
08:30AM  Short Sellers Back Off Big Pharma at 24/7 Wall St.
08:30AM  Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints CNW Group
07:21AM  ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal journal GlobeNewswire
07:00AM  TECOS, Merck's Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes CNW Group
Jun-09-15 06:00PM  Drug switch study bolsters case for copies of biotech medicine
11:00AM  Vaccine Kicked Rotavirus To The Curb In A Few Short Years at Forbes
Jun-08-15 04:57PM  Giant Study Boosts Januvia, Merck's $6 Billion Drug at Forbes
04:30PM  TECOS, Mercks Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes Business Wire
04:30PM  No heart safety issues seen with Merck Januvia diabetes drug -study
02:03PM  This Technology Could Disrupt U.S. Pharma Stocks, Credit Suisse Says
01:00PM  Autoimmune Drugs to Drive Big Pharma Higher in Coming Years at 24/7 Wall St.
10:30AM  Why prescription drugs cost so much
09:05AM  DuPont, Merck Among Stocks To Push Technicals To Negative For The Dow at Forbes
08:25AM  Boston's Intarcia now one step closer to upending type 2 diabetes market at bizjournals.com
07:39AM  Is The 21st Century Cures Act Good Or Bad For The Biopharmaceutical Industry? at Forbes
07:30AM  Merck, New England Patriots Boss Bet $30M on Antibiotics Startup, Spero at Forbes
07:00AM  Illumina, Merck KGaA, Darmstadt, Germany, and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment Business Wire
Jun-05-15 11:43AM  UPDATE: Gilead Sciences: What Game Theory Teaches Us About Hepatitis C at Barrons.com
Jun-04-15 03:04PM  U.S. lawmakers eyeing stronger protections for pregnant workers Reuters
02:25PM  Agenus Gains after Merck Extends Immuno-Oncology Ties - Analyst Blog
09:31AM  Merck's Quest To Revive The Market For Insomnia Drugs at Forbes
Jun-03-15 05:00PM  Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine Business Wire
09:59AM  Amgen: The Quiet Winner at Barrons.com
08:09AM  Why Sigma-Aldrichs stock is falling
Jun-02-15 01:23PM  ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate at Forbes
01:08PM  Tests for new cancer drugs not reliable enough, doctors say
10:30AM  Merck's Keytruda under Priority Review for Lung Cancer - Analyst Blog
09:55AM  An Immunotherapy To Treat Brain Cancer Rises In The Wake Of A Public Loss at Forbes
Jun-01-15 07:35PM  FDA Grants Priority Review for Merck Lung Cancer Treatment at The Wall Street Journal
05:12PM  Merck KGaA sees immunotherapy drug holding its own in cancer race
04:34PM  FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review Business Wire
02:17PM  Bristol-Myers Squibb: Recovering at Barrons.com
02:10PM  Puma Biotech is an opportunity: Pro
01:08PM  Merck's fight against cancer
11:16AM  Pfizer CEO: Ibrance drug well received by physicians
10:37AM  Will Big Pharma Cancer Drug Collaborations Set The Stage For Lower Drug Costs? at Forbes
08:30AM  Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies Business Wire
08:00AM  Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types Business Wire
05:00AM  After BMY's drop, cancer drug stocks set to move? at CNBC
04:16AM  Soaring Cost, Toxic Effects Drive Race for Cancer Tests
12:00AM  Soaring Cost, Toxic Effects Drive Race for Better Cancer Tests at Bloomberg
May-31-15 10:29PM  U.S. Drug Shortages Frustrate Doctors, Patients
May-30-15 02:00PM  TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA(R) (Pembrolizumab) GlobeNewswire
May-29-15 10:45PM  Bristols Shares Take Hit From Cancer-Drug Results at The Wall Street Journal
09:45PM  Merck Takes Aim at Gilead. Should You Worry? at Investopedia
08:21PM  Bristol's Shares Take Hit From Cancer-Drug Results at The Wall Street Journal
05:55PM  Genetic glitch can predict response to new class of cancer drugs
05:01PM  BMY hit on disappointing drug trial
04:22PM  Bristol Sinks On Lung Cancer Data; Merck Up On 2 Trials at Investor's Business Daily
04:00PM  Stocks close lower but post gains for May; data, Greece weigh at CNBC
02:58PM  At ASCO: Bristol, Merck Drugs Shrink Several Tumor Types at Barrons.com
02:18PM  Dow 30 Stock Roundup: GE May Divest Vehicle Management Unit, Merck's Keytruda Gets Favorable Opinion - Analyst Blog
02:06PM  New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status Business Wire
02:05PM  Together, Genetic Test And Drug Unleash Immune System Against Tumors at Forbes
02:05PM  First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Mercks KEYTRUDA® (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine Business Wire
02:00PM  Merck Drug Helps Colon Cancer Patients With DNA Repair Defect at Bloomberg
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck & Co. Inc formerly operated as a subsidiary of Merck KGaA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schechter Adam HEVP & Pres-Global Human HealthMay 11Sale60.4410,634642,7680May 11 05:48 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Option Exercise35.2846,2081,630,39670,353May 11 01:33 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Sale60.9938,3682,339,94931,985May 11 01:33 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise39.2956,0642,202,755206,496May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Sale60.2056,0643,374,795150,432May 05 04:46 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,818025,359May 05 04:46 PM
Golestani ClarkEVP & Chief Info OfficerMay 02Option Exercise0.002,291010,259May 05 04:46 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 02Option Exercise0.008,6540116,334May 05 04:46 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 02Option Exercise0.004,709015,129May 05 04:46 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 02Option Exercise0.003,818034,534May 05 04:46 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 02Option Exercise0.0019,343019,343May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 02Option Exercise0.0011,7080156,503May 05 04:46 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 02Option Exercise0.003,818020,794May 05 04:46 PM
Deese Willie AExe V-P & Pres. MMDMay 02Option Exercise0.007,6360122,631May 05 04:46 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthMay 02Option Exercise0.005,090014,564May 05 04:46 PM
Holston Michael JEVP, LegalApr 29Option Exercise44.39135,6246,020,460135,624Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Option Exercise38.51156,9026,042,441301,697Apr 29 06:01 PM
Holston Michael JEVP, LegalApr 29Sale59.8495,6245,722,54240,000Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Sale59.82156,9029,386,646144,795Apr 29 06:01 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise33.835,000169,15011,400Apr 13 05:24 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOAug 11Option Exercise34.2012,875440,272345,562Aug 12 09:01 AM
FRAZIER KENNETH CChairman, President & CEOAug 11Sale57.0010,058573,306335,504Aug 12 09:01 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Option Exercise45.3823,4001,061,82042,844Aug 05 09:56 AM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerAug 04Sale56.6428,6691,623,72014,175Aug 05 09:56 AM
REPRESAS CARLOS EDirectorAug 01Option Exercise35.195,000175,9505,500Aug 05 10:16 AM
FRAZIER KENNETH CChairman, President & CEOJul 10Option Exercise34.2012,876440,307351,474Jul 10 03:47 PM
FRAZIER KENNETH CChairman, President & CEOJul 10Sale58.039,987579,545341,487Jul 10 03:47 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Option Exercise30.01180,0475,403,278273,611Jul 08 02:16 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJul 07Sale59.16180,04710,650,93293,564Jul 08 02:16 PM